Shares of Outset Medical, Inc. (NASDAQ:OM - Get Free Report) have earned a consensus recommendation of "Hold" from the five brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $10.00.
Several equities analysts recently issued reports on the company. Wall Street Zen upgraded Outset Medical from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Weiss Ratings lowered shares of Outset Medical from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, August 21st.
Read Our Latest Analysis on OM
Outset Medical Stock Performance
Shares of OM stock opened at $3.59 on Monday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 4.11 and a current ratio of 5.19. Outset Medical has a one year low of $3.00 and a one year high of $16.16. The company's 50-day simple moving average is $4.42 and its 200-day simple moving average is $4.19. The stock has a market capitalization of $67.49 million, a price-to-earnings ratio of -0.88 and a beta of 1.90.
Outset Medical (NASDAQ:OM - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. The firm had revenue of $31.64 million during the quarter, compared to the consensus estimate of $28.97 million. Equities analysts anticipate that Outset Medical will post -3.81 earnings per share for the current fiscal year.
Institutional Trading of Outset Medical
Several hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc acquired a new stake in Outset Medical in the 2nd quarter valued at about $34,000. BNP Paribas Financial Markets grew its stake in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company's stock worth $40,000 after purchasing an additional 2,034 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Outset Medical by 4.1% in the 1st quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company's stock worth $239,000 after purchasing an additional 2,435 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Outset Medical by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company's stock worth $1,486,000 after purchasing an additional 3,104 shares in the last quarter. Finally, Barclays PLC lifted its stake in Outset Medical by 9.8% during the fourth quarter. Barclays PLC now owns 37,682 shares of the company's stock valued at $140,000 after purchasing an additional 3,356 shares during the last quarter.
Outset Medical Company Profile
(
Get Free Report)
Outset Medical is a medical technology company specializing in innovations for renal care. The company's flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.
Tablo's modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Outset Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outset Medical wasn't on the list.
While Outset Medical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
